[Skip to Navigation]
March 1976

Clinical Evaluation of Clotrimazole: A Broad-Spectrum Antifungal Agent

Author Affiliations

From the Medical Department, Delbay Pharmaceuticals, Inc, Bloomfield, NJ.

Arch Dermatol. 1976;112(3):350-352. doi:10.1001/archderm.1976.01630270030007

• The efficacy and safety of the broadspectrum, topically applied antifungal agent clotrimazole were evaluated in two double-blind, multicentric trials. Ten investigators reported on a total of 1,361 cases in which a 1% solution or a 1% cream formulation was compared with its respective vehicle. Clotrimazole was therapeutically effective, as confirmed by mycological cure (negative microscopy and culture) and clinical improvement, in tinea pedis, tinea cruris, tinea corporis, pityriasis versicolor, and cutaneous candidiasis. Furthermore, species identification established the efficacy of clotrimazole against Trichophyton rubrum, T mentagrophytes, Epidermophyton floccosum, Microsporum canis, Malassezia furfur (Pityrosporum orbiculare), and Candida albicans. Safety was demonstrated by the low incidence of possibly drug-related adverse experiences, namely, 19 (2.7%) of 699 patients who were treated with clotrimazole, of whom four (0.6%) discontinued treatment.

(Arch Dermatol 112:350-352, 1976)

Add or change institution